Study of biomarkers in MSI-high colorectal cancer patients on immunotherapy
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial is studying people with a specific type of advanced colorectal cancer (MSI-high/dMMR) who are starting immunotherapy with pembrolizumab. The goal is to find out which markers in the tumor might predict whether the treatment works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have colorectal cancer that has spread to other parts of the body (metastatic) and cannot be removed by surgery.
- Your tumor has a specific genetic feature called MSI-high or dMMR (your doctor can test for this).
- You are about to start immunotherapy (pembrolizumab) as your first treatment for this cancer stage.
- You have not had immunotherapy or chemotherapy for this cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a simple blood test (ctDNA) can help guide treatment with immunotherapy drugs (PD-1 inhibitors) for people with a specific type of colon cancer (MSI-high/dMMR). The goal is to see if this approach can improve outcomes and reduce side effects compared to standard care.
This trial tests giving immunotherapy (a drug that boosts your immune system to fight cancer) with or without radiation before surgery for colorectal cancer that is MSI-High or dMMR. It aims to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of two medications, an immunotherapy (QL1706) and a blood-vessel-blocking drug (bevacizumab), for people with a type of colorectal cancer that has a specific genetic feature (MSI-H/dMMR). The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
This trial is studying whether some people with a specific type of advanced colorectal cancer (MSI-H/dMMR) might be able to skip surgery after immunotherapy. Doctors will use a blood test (MRD monitoring) to track the cancer, and then decide whether to keep an eye on it or operate.
This Phase 2 trial tests KN035 in people with advanced or spread-out tumors that have specific genetic markers (MSI-H or dMMR). If you qualify, the study team will look at how well the drug works and how it affects side effects in that group.
Hear when a new Microsatellite Instability-High Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.